Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 2.0 | 4.0 |
Min SIP Amount | ₹99 | ₹100 |
Expense Ratio | 1.93 | 1.88 |
NAV | ₹38.58 | ₹39.95 |
Fund Started | 11 Jun 2018 | 25 Jun 2018 |
Fund Size | ₹2908.21 Cr | ₹6103.96 Cr |
Exit Load | Exit load of 1% if redeemed within 1 year. | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 1.88% | 6.50% |
3 Year | 21.75% | 28.47% |
5 Year | 18.42% | 20.94% |
1 Year
3 Year
5 Year
Equity | 99.63% | 95.89% |
Cash | 0.37% | 4.11% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 10.74% |
Divi's Laboratories Ltd. | 8.02% |
Glenmark Pharmaceuticals Ltd. | 7.24% |
Aurobindo Pharma Ltd. | 6.41% |
Cipla Ltd. | 6.11% |
Apollo Hospitals Enterprise Ltd. | 5.98% |
Lupin Ltd. | 4.94% |
Dr. Reddy's Laboratories Ltd. | 4.13% |
Krishna Institute of Medical Sciences Ltd | 3.81% |
Cohance Lifesciences Ltd. | 3.56% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 11.69% |
Dr. Reddy's Laboratories Ltd. | 8.85% |
Divi's Laboratories Ltd. | 8.13% |
Cipla Ltd. | 7.54% |
Aurobindo Pharma Ltd. | 5.71% |
Lupin Ltd. | 5.11% |
Mankind Pharma Ltd. | 3.88% |
Alkem Laboratories Ltd. | 3.83% |
Biocon Ltd. | 3.64% |
Gland Pharma Ltd. | 3.20% |
Name | Vrijesh Kasera | Dharmesh Kakkad |
Start Date | 03 Feb 2023 | 23 Feb 2021 |
Name
Start Date
Description | The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sectors in India. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 11 Jun 2018 | 25 Jun 2018 |
Description
Launch Date